Last reviewed · How we verify
SOK583A1
SOK583A1 is a small molecule drug that targets the molecular target.
SOK583A1 is a small molecule drug that targets the molecular target. Used for Metastatic non-small cell lung cancer.
At a glance
| Generic name | SOK583A1 |
|---|---|
| Sponsor | Sandoz |
| Drug class | small molecule |
| Target | target |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
It works by binding to the target, which leads to a specific therapeutic effect. This mechanism is still under investigation.
Approved indications
- Metastatic non-small cell lung cancer
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration (PHASE3)
- Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit (PHASE3)
- Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |